Kobaner GB, et al. - Since data on the use of biologic therapies for psoriasis during pregnancy are sparse with even more limited knowledge about the long‐term safety of in utero exposure, researchers retrospectively assessed nine pregnancies in six women with psoriasis who were exposed to biologic therapies between 2006 and 2019 in the psoriasis clinic, a tertiary referral center in Turkey. Pregnancy outcomes involved the delivery of seven healthy babies without any complications, one elective abortion, and one ectopic pregnancy. Based on up‐to‐date collective data in the literature and our real‐life clinical experience provided here, exposure to biologic therapies during pregnancy for psoriasis does not appear to be correlated with adverse pregnancy or neonatal outcomes. The findings are also reassuring with regard to the long-term outcomes of exposed children, but more large prospective studies need to be confirmed. However, the use of biologic therapies during late pregnancy, especially during the third trimester, should be reserved for high‐need patients with psoriasis and should certainly require a delicate risk/benefit balance on a case‐by‐case basis.